Congenital cytomegalovirus infection is the most common cause of nonhereditary sensorineural hearing loss and an important cause of psychomotor retardation. Earlier studies showed that 6-weeks’ treatment with ganciclovir, starting in the neonatal period, prevented hearing deterioration at 6 months, but in one-fifth of the infants, the effect was not sustained at age 12 months. The aim of this preliminary retrospective study was to investigate the effectiveness and safety of long-term treatment with ganciclovir/valganciclovir for congenital cytomegalovirus infection. Twenty-three infants with culture-proven symptomatic congenital cytomegalovirus infection were treated with ganciclovir for 6 weeks followed by oral valganciclovir to age 12 months. Audiometry was performed at least three times in the first year, in addition to physical examination including neurological and developmental assessment. At age ≥1 year, hearing was normal in 76% of affected ears compared to baseline (54%). In 25 normal ears at birth no deterioration was found at ≥1 year. These results were significantly better than reported in a historical control group of similar infants treated for 6 weeks only (P= 0.001). Viral load monitoring demonstrated sustained virological response. Four of the children (18%) had mental retardation. The main side effect of treatment was transient neutropenia. In conclusion, prolonged therapy of symptomatic congenital CMV infection with intravenous ganciclovir followed by oral valganciclovir is safe, and it appears to lead to a better auditory outcome than short-term treatment.
Ganciclovir Valganciclovir Congenital CMV
Peripherally inserted central venous catheter
Real-time polymerase chain reaction
This is a preview of subscription content, log in to check access.
We would like to thank Phyllis Curchack Kornspan for her editorial and secretarial services.
Conflicts of interest
All authors have no conflicts of interest.
Boeckh M, Huang M, Ferrenberg J et al (2004) Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 42:1142–1148CrossRefPubMedGoogle Scholar
Demmler GJ (1991) Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 13:315–329PubMedGoogle Scholar
Dollard SC, Grosse SD, Ross DS (2007) New estimates of prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17:355–363CrossRefPubMedGoogle Scholar
Elek SD, Stern H (1974) Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1:1–5CrossRefPubMedGoogle Scholar
Fan-Harvard P, Nahata MC, Brady MC (1989) Ganciclovir—a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections. J Clin Pharm Ther 14:329–340CrossRefGoogle Scholar
Fowler KB, McCollister FB, Dahle AJ et al (1997) Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 130:624–630CrossRefPubMedGoogle Scholar
Fowler KB, Stango S, Pass RF et al (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663–667PubMedCrossRefGoogle Scholar
Galli L, Novelli A, Chiappini C et al (2007) Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. Pediatr Infect Dis J 26:451–453CrossRefPubMedGoogle Scholar
Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253–276CrossRefPubMedGoogle Scholar
Kimberlin DW, Acosta EP, Sánchez PJ et al (2008) Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 197:836–845CrossRefPubMedGoogle Scholar
Kimberlin DW, Lin CY, Sanchez PJ et al (2003) Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 143:16–25CrossRefPubMedGoogle Scholar
Michaels M, Greenberg DP, Sabo DL, Wald ER (2003) Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J 22:504–508CrossRefPubMedGoogle Scholar